Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3002 in healthy participants and mild to moderate asthma
NCT06213844Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2024
- Primary completion
- Jul 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing Placebo with IBI3002 (2 arms). Primary endpoint: Adverse Events and Serious Adverse Events at 36 days. Started Feb 2024; status: completed.
02
Drugs
IBI3002
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06213844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06213844.